| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,,1
* Division of General Surgery, University of Ottawa, Ottawa, Ontario, Canada; and
Translational Immunovirology and Biodefense Research Program,
Division of Infectious Diseases, Mayo Clinic and Foundation, Rochester, Minnesota, USA
1 Correspondence: Division of Infectious Diseases, Translational Program in Immunvirology and Biodefense, Mayo Clinic, 200 First St. NW, Rochester, MN 55905, USA. E-mail: badley.andrew{at}mayo.edu
The pathophysiology of sepsis involves excessive lymphocyte apoptosis, which correlates with adverse outcomes, and disordered cytokine production, which may promote host injury. As the protease inhibitor (PI) class of antiretroviral agents is known to prevent apoptosis in vitro, we evaluated their effect on survival, lymphocyte apoptosis, and consequent cytokine production in mice with sepsis induced by cecal ligation and perforation. Mice pretreated with PIs have improved survival (67%; P<0.0005) compared with controls (17%) and a significant (P<0.05) reduction in lymphocyte apoptosis. Even mice receiving therapy beginning 4 h after perforation demonstrated improved survival (50%; P<0.05) compared with controls. PI therapy is also associated with an increase in the Th1 cytokine TNF-
(P<0.05) early in sepsis and a reduction in the Th2 cytokines IL-6 and IL-10 (P<0.05) late in sepsis; despite no intrinsic antibacterial effects, PI also reduced quantitative bacterial blood cultures. The beneficial effects of PI appear to be specific to lymphocyte apoptosis, as lymphocyte-deficient Rag1–/– mice did not experience benefit from treatment with PI. Thus, inhibition of lymphocyte apoptosis by PI is a candidate approach for the treatment of sepsis.—Weaver, J. G. R., Rouse, M. S., Steckelberg, J. M., Badley, A. D. Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis.
Key Words: SIRS • cytokine • lymphocyte • CLP • protease inhibitor
This article has been cited by other articles:
|
|
 |
|
  M. J. Tracz, J. P. Juncos, J. P. Grande, A. J. Croatt, A. W. Ackerman, G. Rajagopalan, K. L. Knutson, A. D. Badley, M. D. Griffin, J. Alam, et al. Renal Hemodynamic, Inflammatory, and Apoptotic Responses to Lipopolysaccharide in HO-1-/- Mice Am. J. Pathol., June 1, 2007; 170(6): 1820 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Hotchkiss, K. W. McConnell, K. Bullok, C. G. Davis, K. C. Chang, S. J. Schwulst, J. C. Dunne, G. P. H. Dietz, M. Bahr, J. E. McDunn, et al. TAT-BH4 and TAT-Bcl-xL Peptides Protect against Sepsis-Induced Lymphocyte Apoptosis In Vivo J. Immunol., May 1, 2006; 176(9): 5471 - 5477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ashare, M. M. Monick, L. S. Powers, T. Yarovinsky, and G. W. Hunninghake Severe Bacteremia Results in a Loss of Hepatic Bacterial Clearance Am. J. Respir. Crit. Care Med., March 15, 2006; 173(6): 644 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Soller, A. Tautenhahn, B. Brune, K. Zacharowski, S. John, H. Link, and A. von Knethen Peroxisome proliferator-activated receptor {gamma} contributes to T lymphocyte apoptosis during sepsis J. Leukoc. Biol., January 1, 2006; 79(1): 235 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Wesche-Soldato, J. L. Lomas-Neira, M. Perl, L. Jones, C.-S. Chung, and A. Ayala The role and regulation of apoptosis in sepsis Innate Immunity, December 1, 2005; 11(6): 375 - 382. [Abstract] [PDF]
|
|
|
|
|
|
D. E. Wesche, J. L. Lomas-Neira, M. Perl, C.-S. Chung, and A. Ayala Leukocyte apoptosis and its significance in sepsis and shock J. Leukoc. Biol., August 1, 2005; 78(2): 325 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Lum, G. Bren, R. McClure, and A. D. Badley Elimination of Senescent Neutrophils by TNF-Related Apotosis-Inducing Ligand J. Immunol., July 15, 2005; 175(2): 1232 - 1238. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
